Ulta Beauty (ULTA) Share Price Rose While American International Group Lowered Its Holding by $325,008; Cam Group Holding A Has Lowered Ultragenyx Pharmaceutical In (RARE) Position by $971,155

Ulta Beauty, Inc. (NASDAQ:ULTA) Logo

Cam Group Holding A decreased its stake in Ultragenyx Pharmaceutical In (RARE) by 50.92% based on its latest 2018Q4 regulatory filing with the SEC. Cam Group Holding A sold 22,585 shares as the company’s stock rose 19.90% with the market. The institutional investor held 21,765 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $946,000, down from 44,350 at the end of the previous reported quarter. Cam Group Holding A who had been investing in Ultragenyx Pharmaceutical In for a number of months, seems to be less bullish one the $3.76 billion market cap company. The stock decreased 3.15% or $2.14 during the last trading session, reaching $65.8. About 408,232 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has risen 36.36% since March 14, 2018 and is uptrending. It has outperformed by 31.99% the S&P500. Some Historical RARE News: 07/03/2018 – ULTRAGENYX PHARMACEUTICAL INC – COHORT 2 PATIENT ENROLLMENT TO BEGIN IN MARCH 2018; DATA EXPECTED IN SECOND HALF OF 2018; 17/04/2018 – FDA: New/Generic Drug Approvals – ULTRAGENYX PHARM INC – Biologic License Application (BLA): 761068 April 17, 2018; 23/04/2018 – ULTRAGENYX ANNOUNCES FILING AND FDA CLEARANCE OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR DTX401, A GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA; 07/03/2018 – ULTRAGENYX: UREAGENESIS NORMALIZED IN ONE PATIENT, UP BY 24 WKS; 22/04/2018 – DJ Ultragenyx Pharmaceutical Inc, Inst Holders, 1Q 2018 (RARE); 23/04/2018 – ULTRAGENYX PHARMACEUTICAL INC – ENROLLMENT IN PHASE 1/2 STUDY OF DTX401 TO BEGIN IN H1 2018, WITH DATA FROM FIRST COHORT EXPECTED IN H2 OF 2018; 30/05/2018 – Rentschler Fill Solutions and Ultragenyx start fill & finish collaboration for the US commercial supply of drug product Mepsevii; 07/05/2018 – Ultragenyx Pharma 1Q EPS 62c; 17/05/2018 – ULTRAGENYX & KYOWA KIRIN REPORT TOPLINE PHASE 3 STUDY RESULTS; 30/04/2018 – Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypoph

American International Group Inc decreased its stake in Ulta Beauty Inc (ULTA) by 4.83% based on its latest 2018Q4 regulatory filing with the SEC. American International Group Inc sold 1,332 shares as the company’s stock rose 5.54% with the market. The institutional investor held 26,241 shares of the 2007 company at the end of 2018Q4, valued at $6.43 million, down from 27,573 at the end of the previous reported quarter. American International Group Inc who had been investing in Ulta Beauty Inc for a number of months, seems to be less bullish one the $18.54B market cap company. The stock decreased 0.93% or $2.93 during the last trading session, reaching $312.51. About 903,284 shares traded or 16.57% up from the average. Ulta Beauty, Inc. (NASDAQ:ULTA) has risen 55.20% since March 14, 2018 and is uptrending. It has outperformed by 50.83% the S&P500. Some Historical ULTA News: 15/03/2018 – Ulta Beauty Sees 1Q EPS $2.43-EPS $2.48; 23/03/2018 – The New League: Ulta Beauty’s Masstige Players; 21/03/2018 – The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Ulta Beauty, Inc. Shareholders and a Lead Plaintiff; 10/03/2018 – Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Filed Against Ulta Beauty, Inc. – Ulta; 15/03/2018 – After-hours buzz: ADBE, AVGO, ULTA & more; 09/03/2018 – The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ulta; 15/03/2018 – ULTA BEAUTY INC – COMPANY APPROVES NEW SHARE REPURCHASE AUTHORIZATION OF $625 MLN; 15/03/2018 – Ulta Beauty 4Q Adj EPS $2.75; 21/03/2018 – Ulta Refutes Reselling Lawsuit, Saying ‘Third Parties’ May Be to Blame; 09/03/2018 – The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ulta Beauty, Inc

Investors sentiment decreased to 1.01 in 2018 Q4. Its down 0.14, from 1.15 in 2018Q3. It turned negative, as 27 investors sold RARE shares while 45 reduced holdings. 24 funds opened positions while 49 raised stakes. 49.53 million shares or 1.53% more from 48.78 million shares in 2018Q3 were reported. 20,687 were reported by Legal General Gru Public Limited. Verity Asset Management Incorporated holds 0.44% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 7,581 shares. 62 are owned by Us National Bank De. Northern accumulated 0.01% or 580,580 shares. Moreover, Macquarie Grp has 0.03% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 356,202 shares. Campbell & Investment Adviser Lc holds 0.42% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 8,790 shares. 173,700 were accumulated by Point72 Asset Ltd Partnership. Balyasny Asset Mngmt Limited Liability Corp reported 14,648 shares. Geode Cap Mgmt Lc accumulated 0.01% or 568,230 shares. Federated Investors Pa owns 1.28M shares for 0.15% of their portfolio. Profund Advisors Ltd invested in 13,949 shares or 0.04% of the stock. Tekla Cap Mgmt Ltd Liability Co stated it has 76,958 shares. State Of New Jersey Common Pension Fund D holds 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) or 9,400 shares. Rhumbline Advisers holds 0.01% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) or 65,561 shares. Capital Research Glob owns 5.86M shares for 0.09% of their portfolio.

More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Nasdaq.com which released: “Canada Rare Earth – In the Business of Rare Earths – February 2019 Corporate Update – Nasdaq” on February 28, 2019, also Nasdaq.com with their article: “Rare disease biotech Mereo BioPharma officially withdraws $70 million US IPO – Nasdaq” published on February 21, 2019, Nasdaq.com published: “Albireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC) – Nasdaq” on February 28, 2019. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Nasdaq.com and their article: “Chiasma to Participate in Three Investor Conferences in March – Nasdaq” published on March 04, 2019 as well as Nasdaq.com‘s news article titled: “In rare move, U.S. judge orders acquittal of Barclays currency trader – Nasdaq” with publication date: March 04, 2019.

Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on May, 6. They expect $-1.75 EPS, down 382.26% or $2.37 from last year’s $0.62 per share. After $-1.73 actual EPS reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 1.16% negative EPS growth.

Cam Group Holding A, which manages about $6.91B US Long portfolio, upped its stake in Alphabet Inc by 1,245 shares to 486,916 shares, valued at $504.26 million in 2018Q4, according to the filing. It also increased its holding in At&T Inc (NYSE:T) by 21,877 shares in the quarter, for a total of 77,219 shares, and has risen its stake in Aramark (NYSE:ARMK).

Investors sentiment decreased to 0.99 in 2018 Q4. Its down 0.07, from 1.06 in 2018Q3. It dropped, as 61 investors sold ULTA shares while 193 reduced holdings. 93 funds opened positions while 158 raised stakes. 54.21 million shares or 8.65% more from 49.89 million shares in 2018Q3 were reported. Huntington Bankshares has invested 0% of its portfolio in Ulta Beauty, Inc. (NASDAQ:ULTA). Capital Fund Sa, France-based fund reported 8,882 shares. Qcm Cayman Ltd invested in 1.41% or 1,414 shares. Carroll Finance Associates holds 0.01% in Ulta Beauty, Inc. (NASDAQ:ULTA) or 329 shares. Robecosam Ag holds 0.17% or 15,381 shares in its portfolio. Shelton, a California-based fund reported 5,771 shares. Washington Cap Inc owns 0.51% invested in Ulta Beauty, Inc. (NASDAQ:ULTA) for 1,800 shares. Catalyst Cap Advsrs Ltd Liability Corporation invested in 0.45% or 49,400 shares. Efg Asset (Americas) holds 25,200 shares or 2.22% of its portfolio. Sector Pension Inv Board has invested 0.01% in Ulta Beauty, Inc. (NASDAQ:ULTA). The Tennessee-based Ftb has invested 0% in Ulta Beauty, Inc. (NASDAQ:ULTA). Advisory Rech reported 0.02% stake. State Bank Of Montreal Can reported 41,644 shares. Gateway Invest Advisers Ltd Liability reported 2,719 shares. Robeco Institutional Asset Mgmt Bv, Netherlands-based fund reported 15,815 shares.

More notable recent Ulta Beauty, Inc. (NASDAQ:ULTA) news were published by: Streetinsider.com which released: “Nomura/Instinet Downgrades ULTA Salon (ULTA) to Neutral – StreetInsider.com” on February 19, 2019, also Benzinga.com with their article: “4 Stocks Moving In Thursday’s After-Hours Session – Benzinga” published on March 14, 2019, Benzinga.com published: “A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Earnings, Economic Data – Benzinga” on March 14, 2019. More interesting news about Ulta Beauty, Inc. (NASDAQ:ULTA) were released by: Nasdaq.com and their article: “Noteworthy Tuesday Option Activity: ULTA, BIG, TTWO – Nasdaq” published on February 12, 2019 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For February 19, 2019 – Benzinga” with publication date: February 19, 2019.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Institutional Positions Chart